Last updated on February 2016

Treatment of SFA Lesions With 480 Biomedical STANZA Drug-Eluting Resorbable Scaffold (DRS) System

Brief description of study

An evaluation of the safety and performance of the STANZA Drug-eluting Resorbable Scaffold (DRS) system for the treatment of patients with obstructive superficial femoral artery disease.

Detailed Study Description

The STANZA DRS system is comprised of a controlled release paclitaxel-eluting bioresorbable scaffold and a delivery system used in the treatment of superficial femoral artery disease.

Clinical Study Identifier: NCT02097082

Contact Investigators or Research Sites near you

Start Over

Florian Wolf, MD

Cardiovascular and Interventional Radiology- AKH
Vienna, Austria
  Connect »

Martin Werner, MD

WGKK - Hanusch-Krankenhaus
Vienna, Austria
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.